Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 33

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 33
---
 and regulatory milestones. During the years ended December 31, 2024 and 2023, the Company received €5.6 million and €1.9 million, respectively, in milestone payments from uniQure and recognized investment income of $6.6 million and $2.2 million, respectively, related to the achievement of the milestones during the period. As of December 31, 2024, there were €29.7 million ($31.0 million as of December 31, 2024) in remaining milestones which have not been paid or achieved and have not been recognized in the consolidated financial statements. Proceeds contingent upon the achievement of the remaining milestones will be recognized as investment income in the period in which any uncertainty regarding realization is substantially resolved, which may not occur until the achievement of the underlying milestones. It is at least reasonably possible that some or all of the proceeds contingent upon these milestones will not be realized by the Company.

5. Property and Equipment, NetProperty and equipment, net consists of the following (in thousands): 

        As of December 31,

        2024

        2023

        Laboratory and manufacturing equipment
         
        $
        77,141

        $
        75,632

        Computer equipment and software

        4,244

        4,700

        Furniture and fixtures

        7,031

        7,052

        Leasehold improvements

        101,465

        101,927

        Total property and equipment

        189,881

        189,311

        Accumulated depreciation and amortization

        (72,292
        )

        (57,208
        )

        Property and equipment, net
         
        $
        117,589

        $
        132,103

      During the years ended December 31, 2024, 2023 and 2022, the Company recorded depreciation and amortization expense of $16.2 million, $17.3 million and $12.9 million, respectively.In March 2024, the Company entered into an agreement to sublease its office facilities in New York, New York. In connection with the sublease, the Company recorded impairment of property and equipment of $0.7 million in the first quarter of 2024 related to furniture and fixtures and leasehold improvements located at the subleased facility. Please refer to Note 6 for further information regarding the sublease agreement and associated impairment of